Melatonin as a Potential Therapeutic Tool in Allergic Rhinitis Induced by House-Dust Mite

Year 2023, Volume: 44 Issue: 3, 436 - 443, 29.09.2023

Ayşe Sezim Şafak Pakize Neslihan Taşlı Ezgi Avşar Abdik Hüseyin Abdik Fikrettin Şahin

https://doi.org/10.17776/csj.1202272

Abstract

Melatonin is known as an important regulator of circadian rhythm in humans. In the literature, there are no studies evaluating the efficacy of melatonin in the management of allergic rhinitis (AR) or nasal polyps (Np). Np tissue was taken from nasal cavity and mucosal tissue (Mu) was taken from the nasal septal area. Melatonin (25-200nM) and Mite Allergen (2.5-12.5%) were prepared in complete media. Cell viability, apoptosis, intracellular reactive oxygen species production and gene expression levels were determined. Our results showed that there is no toxic effect of Melatonin, Mite and their combination which was given to Np-MSCs and Mu-MSCs. Melatonin significantly reduced reactive oxygen species levels in both mite-treated Np-MSCs and Mu-MSCs. Indoleamine 2,3-dioxygenase level was significantly decreased in melatonin-treated cells. Cyclooxygenase-1 level was significantly decreased in melatonin-treated healthy and allergic Np-MSCs while there was no significant difference in 100 and 150nM Melatonin-treated Mu-MSCs. Interestingly, 50nM Melatonin significantly increased Cyclooxygenase-1 level in Mu-MSCs. 50, 100 and 150nm Melatonin significantly decreased Interleukin-6 level in Mite-treated Np-MSCs. In addition, 100 and 150nM Melatonin significantly decreased Interleukin-6 level in Mite-treated Mu-MSCs. Melatonin has well-established anti-oxidant and anti-neoplastic activity, could be a promising therapeutic agent in the treatment of AR and nasal polyposis.

Keywords

Melatonin mite allergen, Allergic rhinitis, Nasal polyp tissue, Mucosal tissue, Mesenchymal stem cell.

References

• [1] Meltzer E.O., Allergic Rhinitis: Burden of Illness, Quality of Life, Comorbidities, and Control, Immunol. Allergy Clin. North Am., 36 (2016) 235–48.
• [2] Craig T.J., Ferguson B.J., Krouse J.H, Sleep impairment in allergic rhinitis, rhinosinusitis, and nasal polyposis, Am. J. Otolaryngol., 29 (2008) 209–17.
• [3] Marseglia L., D’Angelo G., Manti S., et al., Melatonin and atopy: role in atopic dermatitis and asthma, Int. J. Mol. Sci., 15 (2014) 13482–93.
• [4] Ciprandi G., Caimmi D., Del Giudice M.M., La Rosa M., Salpietro C., Marseglia G.L.,: Recent developments in united airways disease, Allergy Asthma Immunol. Res., 4 (2012) 171–7.
• [5] Vorsprach M., Arens C., Knipping S., et al., Expression of COX-1, COX-2, 5-LOX and CysLT2 CysLT2 in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease, Allergy Asthma Clin. Immunol., 15 (2019) 1–14.
• [6] Refaat M.M., Abdel Rehim A.S.M., El-Sayed H.M., Mohamed N.A., Khafagy A.G., Serum indolamine 2, 3 dioxygenase as a marker in the evaluation of allergic rhinitis, Am. J. Rhinol Allergy, 29 (2015) 329–33.
• [7] D’Elia C., Gozal D., Bruni O., Goudouris E., e Cruz MM: Allergic rhinitis and sleep disorders in children--coexistence and reciprocal interactions, J Pediatr (Rio J) 98(5) (2021) 444-454.
• [8] Reiter R.J., Pineal melatonin: cell biology of its synthesis and of its physiological interactions, Endocr. Rev., 12 (1991) 151–80.
• [9] Mauriz J.L., Collado P.S., Veneroso C., Reiter R.J., González-Gallego J., A review of the molecular aspects of melatonin’s anti-inflammatory actions: recent insights and new perspectives, J. Pineal Res., 54 (2013) 1–14.
• [10] Hacısevki A., Baba B., An overview of melatonin as an antioxidant molecule: a biochemical approach, Melatonin Mol. Bio.l Clin. Pharm. Approaches, (2018) 59–85.
• [11] Li Y., Li S., Zhou Y., et al., Melatonin for the prevention and treatment of cancer, Oncotarget, 8 (2017) 39896.
• [12] Lu T., Galijasevic S., Abdulhamid I., Abu-Soud H.M., Analysis of the mechanism by which melatonin inhibits human eosinophil peroxidase, Br. J. Pharmacol., 154 (2008) 1308–17.
• [13] Kim T.H., Jung J.A., Kim G.D., et al., Melatonin inhibits the development of 2, 4-dinitrofluorobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice, J. Pinea.l Res., 47 (2009) 324–9.
• [14] Wang Y.T., Chen S.L., Xu S.Y., Effect of melatonin on the expression of nuclear factor-kappa B and airway inflammation in asthmatic rats, Chinese J. Pediatr., 42 (2004) 94–7.
• [15] Fidan V., Alp H.H., Gozeler M., Karaaslan O., Binay O., Cingi C., Variance of melatonin and cortisol rhythm in patients with allergic rhinitis, Am. J. Otolaryngol., 34 (2013) 416–9.
• [16] Pawankar R., Canonica G.W., Holgate S.T., Lockey R.F., Blaiss M.S., WAO White Book on Allergy: Updates 2013, World Allergy Organization, (2013).
• [17] Hosoki K., Gandhe R., Boldogh I., Sur S., Reactive oxygen species and allergic responses. In: Systems biology of free radicals and antioxidants. Berlin: Springer-Verlag Heidelberg, (2012) 3239–3266.
• [18] Gostner J.M., Becker K., Kofler H., Strasser B., Fuchs D., Tryptophan metabolism in allergic disorders, Int. Arch. Allergy Immuno.,l 169 (2016) 203–15.
• [19] Shin I.S., Park J.W., Shin N.R., et al., Melatonin reduces airway inflammation in ovalbumin-induced asthma, Immunobiology, 219(2014) 901–8.
• [20] Wu H.M., Shen Q.Y., Fang L., et al., JNK--TLR9 signal pathway mediates allergic airway inflammation through suppressing melatonin biosynthesis, J. Pineal. Res., 60 (2016) 415–23.
• [21] Shin I.S., Park J.W., Shin N.R., et al., Melatonin inhibits MUC 5 AC production via suppression of MAPK signaling in human airway epithelial cells, J. Pineal Res., 56 (2014) 398–407.
• [22] Gumral N., Naziroglu M., Ongel K., et al., Antioxidant enzymes and melatonin levels in patients with bronchial asthma and chronic obstructive pulmonary disease during stable and exacerbation periods, Cell Biochem. Funct. 27(5) (2009) 276–83.
• [23] Bayrak Degirmenci P., Aksun S., Altin Z., et al.: Allergic rhinitis and its relationship with IL-10, IL-17, TGF-$β$, IFN-$γ$, IL 22, and IL-35, Dis. Markers, (2018) 9131432.
• [24] Sarnowski C., Laprise C., Malerba G., et al., DNA methylation within melatonin receptor 1A (MTNR1A) mediates paternally transmitted genetic variant effect on asthma plus rhinitis, J. Allergy Clin. Immunol., 138 (2016) 748–53.
• [25] Chang Y.S., Lin M.H., Lee J.H., et al., Melatonin supplementation for children with atopic dermatitis and sleep disturbance: a randomized clinical trial, JAMA Pediatr, 170 (2016) 35–42.
• [26] Chen C.F., Wang D., Reiter R.J., Yeh D.Y., Oral melatonin attenuates lung inflammation and airway hyperreactivity induced by inhalation of aerosolized pancreatic fluid in rats, J. Pineal Res., 50 (2011) 46–53.
• [27] Hopkins C., Chronic rhinosinusitis with nasal polyps, N. Engl. J. Med., 381 (2019) 55–63.
• [28] Tomassen P., Vandeplas G., Van Zele T., et al., Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers, J. Allergy Clin. Immunol., 137 (2016) 1449–56.
• [29] Newton J.R., Ah-See K.W., A review of nasal polyposis, Ther. Clin. Risk. Manag., 4 (2008) 507.
• [30] DeConde A.S., Mace J.C., Levy J.M., Rudmik L., Alt J.A., Smith T.L., Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis, Laryngoscope, 127 (2017) 550–555.